Clinical stage biopharmaceutical company: Xenetic Biosciences (XBIO)

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is headquartered in Lexington, Massachusetts, USA and has 5 full-time employees. It is a clinical-stage biopharmaceutical company focusing on the discovery, research and development of next-generation biologic drugs and new orphan tumor drugs.

Xenetic Biosciences

Xenetic Biosciences (XBIO):

Xenetic Biosciences’ main research product candidate is the tumor treatment XBIO-101 (Cridamod sodium), which is used to treat progesterone-resistant endometrial cancer.

In addition, PolyXen, Xenetic’s patented drug development platform, enables the next generation of biopharmaceuticals by improving its half-life and other pharmacological properties.

Xenetic Biosciences is conducting business development activities to explore partnerships using its PolyXen delivery platform. The company has signed R&D, licensing and supply agreements with Shire plc , Serum Institute of India, PJSC Pharmsynthez and SynBio LLC.

Notify of
Inline Feedbacks
View all Intels

The world’s largest human resources service company: Adecco Group AG (AHEXY)

One of the world’s top ten fund companies: Schroders plc (SHNWF)